Localized scleroderma and zinc: a pilot study.

Abstract

Esthetic or functional repercussions in localized scleroderma may be considerable. Numerous treatments have been proposed with limited effectiveness. The purpose of this study was to evaluate the efficacy of high-dose zinc gluconate in the treatment of morphea. We are reporting a retrospective study of 17 patients with histologically confirmed localized scleroderma active for more than one year and whose treatment with a high potency dermocorticosteroid was a failure. The patients received 60 to 90 mg of zinc metal daily. The clinical evaluation was performed by the physician and the patient. An efficacy of 53% was obtained (5 partial remissions and 4 complete remissions) with a mean dose of 83.3 mg/day of zinc metal. Two patients (11.8%) had epigastralgia; no discontinuation of zinc gluconate for poor tolerability was noted.We conclude that high-dose zinc gluconate can therefore be a valuable alternative treatment for localized scleroderma, with good tolerability, although placebo-controlled studies are necessary to confirm our results.

• Authors: Anabelle Brocard, Gaelle Quereux, Dominique Moyse, Brigitte Dreno
• Journal: European journal of dermatology : EJD (Eur J Dermatol) 2010 Mar-Apr Vol. 20 Issue 2 Pg. 172-4 ISSN: 1167-1122 [Print] France
• PMID: 20123645 (Publication Type: Journal Article)

Chemical References

• Dermatologic Agents
• Gluconates
• Zinc
• gluconic acid

Topics

• Administration, Oral
• Adult
• Aged
• Dermatologic Agents (therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Gluconates (therapeutic use)
• Humans
• Male
• Middle Aged
• Pilot Projects
• Remission Induction
• Retrospective Studies
• Scleroderma, Localized (drug therapy)
• Zinc (therapeutic use)